Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Cell Dev. Biol.

Sec. Molecular and Cellular Pathology

Volume 13 - 2025 | doi: 10.3389/fcell.2025.1698110

This article is part of the Research TopicEditors’ Showcase 2025: Insights in Molecular and Cellular PathologyView all articles

Research progress on the application of nanoparticles delivery in the treatment of atherosclerosis: implications for therapeutic interventions

Provisionally accepted
  • 1West China Hospital of Sichuan University, Chengdu, China
  • 2West China Second University Hospital, Sichuan University, Chengdu, China

The final, formatted version of the article will be published soon.

Atherosclerosis (AS) is a chronic cardiovascular disease and a leading cause of global morbidity and mortality. Its pathological features include lipid accumulation within the arterial walls, macrophage infiltration, and the proliferation of fibrous plaques, which can manifest in various blood vessels throughout the body. The dislodgement of arterial plaques can lead to severe complications, such as myocardial and cerebral infarction. Current therapeutic strategies for AS focused on managing risk factors, including hypertension, and dyslipidemia. However, the adverse effects of medications and the progression of plaques remain challenges. Nanoparticles (NPs), defined as naturally occurring or biosynthesized particles with immunomodulatory properties and sizes ranging from 1 nm to 100 nm, represent a novel drug delivery system. This technology enhances drug stability and targeting specificity while reducing off-target toxicity. NPs encapsulating therapeutic agents or gene-editing components are capable of facilitating transmembrane transport and cross-barrier release, effectively targeting AS plaques to modulate the activity of macrophages and endothelial cells. This mechanism aids in the treatment of plaques and subsequently reduces complications. The advancement of NPs delivery technology offers extensive potential for AS-targeted therapies and personalized medicine. This review aims to summarize recent advances in NP-based delivery systems for AS treatment.

Keywords: Atherosclerosis, Nanoparticles, delivery system, targeted therapy, Therapeutic interventions

Received: 03 Sep 2025; Accepted: 20 Oct 2025.

Copyright: © 2025 Hao, Wang, Zhang, Yu, Mo and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jinhui Wu, wujinhui@scu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.